S. Santhakumaran

Levosimendan to prevent acute organ dysfunction in sepsis: the LeoPARDS RCT

G. Perkins, M. Singer, A. Gordon, 2018, Efficacy and Mechanism Evaluation.

Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis.

Gavin D Perkins, Alexina J Mason, Shalini Santhakumaran, 2016, The New England journal of medicine.

Defining phenotypes and treatment effect heterogeneity to inform acute respiratory distress syndrome and sepsis trials: secondary analyses of three RCTs

J. Laffey, M. Shankar-Hari, K. Delucchi, 2021, Efficacy and Mechanism Evaluation.

Transcriptomic Signatures in Sepsis and a Differential Response to Steroids. From the VANISH Randomized Trial

J. Knight, S. Brett, A. Gordon, 2019, American journal of respiratory and critical care medicine.

Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial.

G. Perkins, S. Brett, M. Cecconi, 2016, JAMA.

Inflammatory sub-phenotypes in sepsis: relationship to outcomes, treatment effect and transcriptomic sub-phenotypes

M. Shankar-Hari, A. Gordon, K. Burnham, 2022, medRxiv.

Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial

G. Perkins, M. Singer, A. Gordon, 2019, Intensive Care Medicine.

Patient stratification using plasma cytokines and their regulators in sepsis: relationship to outcomes, treatment effect and leucocyte transcriptomic subphenotypes

M. Shankar-Hari, K. Burnham, P. Hutton, 2024, Thorax.